Other Affiliated Sites
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Prospectus
Announcements
2023.12.18
PROXY FORM
2023.12.18
NOTIFICATION LETTER
2023.12.18
Circular PROPOSED AMENDMENTS TO THE ARTICLES AND RELATED RULES OF PROCEDURES OF...
2023.12.18
ANNOUNCEMENT PROPOSED AMENDMENTS TO THE ARTICLES
2023.11.23
PROXY FORM FOR THE H SHAREHOLDERS’ CLASS MEETING
2023.11.23
PROXY FORM FOR EXTRAORDINARY GENERAL MEETING
2023.11.23
NOTIFICATION LETTER
2023.11.23
(1) PROPOSED AMENDMENTS TO THE ARTICLES AND RELATED RULES OF PROCEDURES OF THE C...
2023.11.21
PROPOSED AMENDMENTS TO THE ARTICLES AND PROPOSED CHANGE IN USE OF PROCEEDS
2023.10.30
2023 THIRD QUARTERLY REPORT
第一页
上一页
2
3
4
5
6
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.
